[ad_1]
US drugmaker Pfizer and German biotech company BioNTech have a coronavirus vaccine candidate that now shows 90 percent efficiency in phase three tests, the companies said Monday.
According to the companies, the new tests show that the vaccine may be as protective as the type of vaccine children receive against measles.
Researchers previously expected a corona vaccine with at least 75 percent efficiency, writes CNBC.
“Great day for humanity”
Albert Bourla is the CEO of Pfizer and he is satisfied with the result.
– A great day for humanity and for research, he tells CNBC.
Pfizer has tested the vaccine on volunteers who have not had the coronavirus before.
The vaccine provides protection against covid-19 28 days after the first vaccination.
Up to 20 million vaccines
With today’s news, we are one big step closer to giving people around the world a much-needed impact in the global health crisis. We look forward to sharing increased efficiency and safety data in the coming weeks, “Pfizer writes in a statement obtained by CNBC.
According to Pfizer, 15 to 20 million people can be vaccinated before the end of the year, if they get the go-ahead from the authorities.
At the time of writing, the corona virus has claimed more than 1.26 million lives worldwide.
SEE MORE: Mutated coronavirus may not respond to vaccine
Ask the professor why the new mutated variant of the coronavirus could be the start of a new pandemic.
Tegnell: “We are far from where we were this spring”
– There is a long way to go until there is an adequate load on care, says Tegnell
